(Q38315952)

2 September 2017

1 reference

title

Anal cancer: current standards in care and recent changes in practice (English)

1 reference

2 September 2017

Ravi Shridhar

1

1 reference

2 September 2017

David Shibata

series ordinal

2

1 reference

2 September 2017

Emily Chan

series ordinal

3

1 reference

2 September 2017

Charles R Thomas

series ordinal

4

1 reference

2 September 2017

language of work or name

English

0 references

publication date

12 January 2015

1 reference

2 September 2017

1 reference

2 September 2017

volume

65

1 reference

2 September 2017

issue

2

1 reference

2 September 2017

page(s)

139-162

1 reference

2 September 2017

cites work

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Changing patterns of anal canal carcinoma in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Progression of anal high-grade squamous intraepithelial lesions to invasive anal cancer among HIV-infected men who have sex with men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

21 January 2018

Anal cancer: an overview

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Sexual practices, sexually transmitted diseases, and the incidence of anal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Sexually transmitted infection as a cause of anal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Human papillomavirus prevalence in invasive anal cancers in the United States before vaccine introduction

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

The role of human papillomavirus in nongenital cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual and bisexual men: prevalence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Initial prevalence of anal human papilloma virus infection in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Impact of the HIV epidemic on the incidence rates of anal cancer in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the french hospital database on HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

The impact of HIV viral control on the incidence of HIV-associated anal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Cigarette Smoking and the Risk of Anogenital Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

An integrative review of guidelines for anal cancer screening in HIV-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

High-resolution anoscopy targeted surgical destruction of anal high-grade squamous intraepithelial lesions: a ten-year experience

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Condom use in prevention of Human Papillomavirus infections and cervical neoplasia: systematic review of longitudinal studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

HPV vaccine against anal HPV infection and anal intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Treatment of squamous cell carcinoma of the anal canal

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Diagnosis of anal carcinoma--doctor's finger still the best?

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

The 2001 Bethesda System: terminology for reporting results of cervical cytology

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Management of inguinal lymph node metastases in patients with carcinoma of the anal canal: experience in a series of 270 patients treated in Lyon and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11)

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Evaluation of the impact of HIV serostatus, tobacco smoking and CD4 counts on epidermoid anal cancer survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Endoanal ultrasound evaluation of anorectal diseases and disorders: technique, indications, results and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Magnetic resonance imaging of anal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

FDG-PET/CT in the evaluation of anal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

New approach to anal cancer: individualized therapy based on sentinel lymph node biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Value of staging squamous cell carcinoma of the anal margin and canal using the sentinel lymph node procedure: an update of the series and a review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of inguinal node metastases in patients with anal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Limited Value of Staging Squamous Cell Carcinoma of the Anal Margin and Canal Using the Sentinel Lymph Node Procedure: A Prospective Study with Long-Term Follow-Up

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Successful treatment of anogenital Bowen's disease with the immunomodulator imiquimod, and monitoring of therapy by DNA image cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patient

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Imiquimod treatment of anal intraepithelial neoplasia in HIV-positive men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Topical 5-fluorouracil treatment of anal intraepithelial neoplasia in human immunodeficiency virus-positive men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Long-term outcome of ablation of anal high-grade squamous intraepithelial lesions: recurrence and incidence of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Carcinoma of the anal canal, a clinical and pathologic study of 188 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Invasive anal squamous-cell carcinoma in the HIV-positive patient: outcome in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I).

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Long-term follow-up of a Phase II trial of high-dose radiation with concurrent 5-fluorouracil and cisplatin in patients with anal cancer (ECOG E4292).

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

The EGF receptor family as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Shortened irradiation scheme, continuous infusion of 5-fluorouracil and fractionation of mitomycin C in locally advanced anal carcinomas. Results of a phase II study of the European Organization for Research and Treatment of Cancer. Radiotherapy and

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014).

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Anal cancer: an HIV-associated cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for invasive anal carcinoma in human immunodeficiency virus-positive patients receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Intensity-modulated radiotherapy for squamous cell carcinoma of the anal canal: efficacy of a low daily dose to clinically negative regions

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Concurrent chemotherapy and intensity-modulated radiation therapy for anal carcinoma--clinical outcomes in a large National Cancer Institute-designated integrated cancer centre network.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

IMRT for locally advanced anal cancer: clinical experience of the Montpellier Cancer Center

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

RTOG 0529: Intensity modulated radiation therapy and anal cancer, a step in the right direction?

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: a propensity score analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

The effect of intensity-modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Treatment of T3 and T4 anal carcinoma with combined chemoradiation and interstitial 192Ir implantation: a 10-year experience

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

High-dose-rate endorectal brachytherapy for locally advanced rectal cancer in previously irradiated patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Role of brachytherapy in the boost management of anal carcinoma with node involvement (CORS-03 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Elective inguinal node irradiation in early-stage T2N0 anal cancer: prognostic impact on locoregional control

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Outcomes of salvage surgery for squamous cell carcinoma of the anal canal

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Perineal healing and survival after anal cancer salvage surgery: 10-year experience with primary perineal reconstruction using the vertical rectus abdominis myocutaneous (VRAM) flap.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Inferiorly based rectus abdominis myocutaneous flaps in surgical oncology: Indications, technique, and experience in 37 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Treatment options in metastatic squamous cell carcinoma of the anal canal.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a Phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Surgical salvage therapy: abdominoperineal resection for recurrent anal carcinoma, metastasectomy of recurrent colorectal cancer, and esophagectomy after combined chemoradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canal

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Squamous-cell carcinoma of the anal canal: predictors of treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Results of salvage abdominoperineal resection for anal cancer after radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Effect of pelvic radiotherapy for prostate cancer on bowel, bladder, and sexual function: the patient's perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Long-term quality of life after radiotherapy for the treatment of anal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Impaired health-related quality of life after chemoradiotherapy for anal cancer: late effects in a national cohort of 128 survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Comparison of conformal and intensity modulated radiation therapy techniques for treatment of pelvic tumors. Analysis of acute toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Assessment of long-term quality of life in patients with anal carcinomas treated by radiotherapy with or without chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Sexual function in females after radiotherapy for rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Late symptoms in long-term gynaecological cancer survivors after radiation therapy: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Evidence-based treatment of depression in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Toward clinical care guidelines for supporting rehabilitative vaginal dilator use with women recovering from cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

21 January 2018

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

The role of radiation oncologists and discussion of fertility preservation in young cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Gastrointestinal problems after pelvic radiotherapy: the past, the present and the future

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Sexual oncology: sexual health issues in women with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Current management of erectile dysfunction after cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Effects of short term sacral nerve stimulation on anal and rectal function in patients with anal incontinence

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

21 January 2018

Sacral nerve stimulation

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Permanent sacral nerve stimulation for fecal incontinence.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Hyperbaric oxygen: its uses, mechanisms of action and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21259

21 January 2018

Identifiers

DOI

10.3322/CAAC.21259

1 reference

2 September 2017

1 reference